摘要
目的探讨利培酮或喹硫平长期治疗儿童精神疾病后,对肥胖及相关代谢失调的影响。方法选取年龄2~18岁的具有精神类疾病的患者130例作为研究对象,所有患者治疗前均未服用过第二代抗精神药物(SGA),采用自然年度纵向调查法,研究分析了患儿的身体质量指标、生化指标、代谢参数。在12个月的研究周期内,共46例患儿(利培酮组25例,喹硫平组21例)的资料用于分析。结果 SGA治疗12个月后,患儿的体质量显著增加,利培酮组平均增加10.6(7.8~13.6)kg,喹硫平组平均增加9.5(6.3~12.7)kg,两组比较差异有统计学意义(P<0.05)。同时,两组患儿的体质量指数Z(BMI z)评分也显著增高,儿童患超重或者肥胖的发生率也显著增加。快速血糖平均水平及高密度脂蛋白与总胆固醇比值明显增高,增高量分别为0.24(0.04-0.43)mmol·L^(-1)和0.49(0.16~0.81)mmol·L^(-1)。结论儿童抗精神药物治疗12个月期间,儿童腰围显著增加、血脂指标异常,故儿童肥胖及代谢失调的风险显著升高。这一研究结果,对早期发现及代谢副作用治疗的有序检测具有重要意义。
Objective To determine the risk of developing obesity and related metabolic complications in children following long-term treatment with risperidone or quetiapine. Methods One hundred and thirty patients aged 2 to 18 years with mental disorders were in-cluded. And all patients were not taken second-generation antipsychotic drugs. The study design was a 1-year naturalistic prospective longitudinal study. The body mass index,biochemical index and metabolic parameter of the children were studied and analyzed at base-line and months 6 and 12. Data of 46 participants（25 treated with risperidone and 21 treated with quetiapine） who completed 12-month monitoring were analyzed. Results After 12 months of second-generation antipsychotics（SGA） treatment,mean weight increased sig-nificantly by 10. 6（7. 8-13. 6） kg for risperidone and 9. 5（6. 3-12. 7） kg for quetiapine（P 〈 0. 05）. And body mass index z score（BMI z） also increased significantly in both groups（P ＆lt; 0. 05）. There was a high incidence of children becoming overweight or obese. The mean levels of fasting glucose and ratio of total cholesterol to high-density lipoprotein cholesterol increased significantly by 0. 24（0. 03-0. 42） mmol·L - 1 and 0. 49（0. 15-0. 81） mmol·L - 1 ,respectively. Conclusions Children treated with risperidone or quetiapine have significant risks in developing obesity,elevated waist circumference,and dyslipidemia during 12 months of treatment. These data empha-size the importance of regular monitoring for early identification and treatment of metabolic side effects.
出处
《安徽医药》
CAS
2017年第11期2061-2065,共5页
Anhui Medical and Pharmaceutical Journal
关键词
第二代抗精神药物
肥胖
代谢综合征
儿童精神疾病
Second-generation antipsychotic
Obesity
Metabolic dysregulation
Mentaldisorders
